Jazz Pharmaceuticals submits new drug application for solriamfetol (JZP-110) for excessive sleepiness associated with narcolepsy and obstructive sleep apnea. azz Pharmaceuticals plc today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration on December 20, 2017 seeking marketing approval for solriamfetol (JZP-110), an investigational medicine for the treatment of excessive sleepiness…